Impact BioMedical, INC. Impairment of Intangible Assets, Finite-lived
Impact BioMedical, INC. (IBO) reported Impairment of Intangible Assets, Finite-lived of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2026-03-11
- Impact BioMedical, INC. impairment of intangible assets, finite-lived for the quarter ending 2025-12-31 was $0.00.
- Impact BioMedical, INC. impairment of intangible assets, finite-lived for the quarter ending 2025-09-30 was $0.00.
- Impact BioMedical, INC. impairment of intangible assets, finite-lived for the quarter ending 2025-06-30 was $0.00.
- Impact BioMedical, INC. impairment of intangible assets, finite-lived for the quarter ending 2025-03-31 was $0.00.
- Impact BioMedical, INC. impairment of intangible assets, finite-lived for fiscal 2025 was $0.00.
- Impact BioMedical, INC. impairment of intangible assets, finite-lived for fiscal 2024 was $0.00.
- Impact BioMedical, INC. impairment of intangible assets, finite-lived for fiscal 2023 was $0.00.
- Impact BioMedical, INC. impairment of intangible assets, finite-lived for fiscal 2022 was $0.00.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $0.00 derived: sum of 2 quarters · filed 2026-03-11 | $0.00 derived: sum of 3 quarters · filed 2026-03-11 | $0.00 10-K · filed 2026-03-11 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $0.00 derived: sum of 2 quarters · filed 2025-11-07 | $0.00 10-Q · filed 2025-11-07 | $0.00 derived: sum of 4 quarters · filed 2026-03-11 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | $0.00 derived: sum of 3 quarters · filed 2026-03-11 | $0.00 derived: sum of 4 quarters · filed 2026-03-11 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-14 | $0.00 derived: sum of 2 quarters · filed 2026-03-11 | $0.00 derived: sum of 3 quarters · filed 2026-03-11 | $0.00 derived: sum of 4 quarters · filed 2026-03-11 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $0.00 derived: sum of 2 quarters · filed 2026-03-11 | $0.00 derived: sum of 3 quarters · filed 2026-03-11 | $0.00 10-K · filed 2026-03-11 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2025-11-07 | $0.00 derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-13 | $0.00 10-Q · filed 2025-08-14 | $0.00 derived: sum of 3 quarters · filed 2025-05-14 | $0.00 derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-14 | $0.00 derived: sum of 2 quarters · filed 2025-05-14 | $0.00 derived: sum of 3 quarters · filed 2025-05-14 | $0.00 derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $0.00 derived: sum of 2 quarters · filed 2025-03-28 | $0.00 derived: sum of 3 quarters · filed 2025-03-28 | $0.00 10-K · filed 2025-03-28 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-10 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |